JHVEPhoto While four “Mag 7” names report this week, Tuesday morning, July 29th’s release of Boeing’s (NYSE:BA) second quarter 2025 financial results might be more eagerly awaited than the market’s leaders the last few years. For the aerospace and ...

Vancouver, Canada, July 28, 2025 – TheNewswire - Electrum Discovery Corp. (“Electrum” and/or the “Company”) (TSX-V:ELY | FRA:R8N | OTC:ELDCF) is pleased to report the results of voting at its Annual General and Special Meeting (the “Meeting”) held on July 24th, 2025 in Vancouver, Canada. Shareholders voted in favor of all items put forward by the Board of Directors and management.  The Company warmly welcomes Michael Williams and John Anderson who were elected to the board of directors of the Company (the ...

公司公告 - VAALCO Energy将于2025年8月7日纽约证券交易所收盘后发布2025年第二季度财报，并于8月8日中部时间上午9点举行电话会议讨论财务和运营结果 [1][2] - 电话会议提供美国免费拨入号码(833) 685-0907，英国免费号码08082389064，国际拨入号码(412) 317-5741，会议名称为"Vaalco Energy Earnings Conference Call" [2] - 会议将通过公司官网www.vaalco.com进行网络直播，并提供录音回放 [2] 公司背景 - VAALCO Energy成立于1985年，注册地为美国特拉华州，总部位于德克萨斯州休斯顿，是一家独立能源公司 [3] - 公司在加蓬、埃及、科特迪瓦、赤道几内亚、尼日利亚和加拿大拥有多样化的生产、开发和勘探资产组合 [3] 联系方式 - 公司通用及投资者咨询电话+00 1 713 543 3422，官网www.vaalco.com [4] - 美国投资者关系由Al Petrie Advisors负责，英国财经公关由Buchanan负责，联系方式+44 (0) 207 466 5000 [4]

The Invesco KBW Premium Yield Equity REIT ETF (NASDAQ: KBWY ) has an impressive 9.63% dividend yield, putting it on the radar of many income investors. However, the dividend is hiding deeper problems that make it a bad investment.I am a dynamic finance professional with a Master’s in Banking & Finance from Université Paris 1 Panthéon-Sorbonne. My investing background mix corporate finance, M&A, and investment analysis, with a focus on real estate, renewable energy, and equity markets. I specialize in financ ...

Madrid, July 28.- Technology services company Lleida.net (BME: LLN) (EPA: ALLN) (OTCQX: LLEIF) reported EBITDA of €971,000 in the second quarter of 2025, up 33 percent from the same period last year, according to preliminary results presented to the market today.  This growth was driven by a significant increase in revenue from certified electronic notification and contracting services, which grew by double digits. During the period, the company's pre-tax profit reached €296,000, up 97 percent from the sec ...

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or a ...

BW Energy contracts Deepsea Mira for drilling Kudu appraisal well BW Energy, together with NAMCOR E&P, is pleased to announce that it has contracted the Deepsea Mira semi-submersible rig for the drilling of the Kharas appraisal well on the Kudu licence (PPL003) offshore Namibia in the Orange Basin, scheduled for the second half of 2025. The agreement is part of a rig-sharing arrangement previously announced by the rig’s operator, Northern Ocean Ltd., with Rhino Resources Ltd. The contract, entered into by ...

阿尔茨海默病药物研发进展 - 公司宣布在阿尔茨海默病国际会议(AAIC)展示其药物组合最新数据，涵盖从早期症状到临床前阶段的全面治疗方案[1] - 重点包括Phase Ib/IIa Brainshuttle™ AD研究中trontinemab的积极结果：91%受试者淀粉样蛋白斑块清除至PET阴性，ARIA-E发生率低于5%[6][7][8] - 计划2025年启动两项Phase III研究(TRONTIER 1/2)针对早期症状患者，新增Phase III试验针对临床前高风险人群[2][6] 诊断技术突破 - Elecsys® pTau217血液检测获FDA突破性设备认定，性能媲美PET扫描和脑脊液检测，可规模化应用于临床[3][9] - 真实数据显示该检测可避免75%未确诊患者的延误(平均诊断等待2.8年)，减少医疗资源消耗[4][10] - 配套启动TRAVELLER预筛查研究，通过血浆生物标志物扩大试验人群多样性[5] 药物作用机制 - Trontinemab采用Brainshuttle技术增强血脑屏障穿透性，3.6mg/kg剂量组72%患者实现深度清除(淀粉样蛋白水平<11 centiloids)[7][14][15] - 早期显著降低脑脊液和血浆中tau蛋白相关生物标志物(pTau181/217等)，安全性良好[8] - 该双特异性抗体设计针对β淀粉样蛋白聚集形态，可能延缓疾病进展[14][15] 研发战略布局 - 公司阿尔茨海默病产品线覆盖诊断工具(血液检测/CSF/数字技术)与多靶点药物，强调早期干预[16] - 通过TRONTIER研究设计体现综合策略：主要终点为18个月治疗后认知功能改善(CDR-SB量表)，次要终点包括行为症状和生活质量[5][12] - 诊断与治疗协同开发，如pTau217检测将用于临床试验患者筛选[3][9]

I have just returned from a few days’ stay in the United Kingdom where I could not help but enjoy a Guinness beer or two. That is reason enough to review its mother company Diageo, whose investorsExcellent academic Finance background and Finance professional with over five years of cumulative experience in Consulting & Audit Firms including a professional Valuation position, FP&A and Controlling positions, and Financial writing. I often rate hold/neutral, even when my inclination is bullish or bearish. Rati ...

作者背景 - 作者为金融记者 专注于房地产市场研究 拥有10年传播领域经验 [1] - 作者目前在阿根廷经济研究机构CEEAXXI和国际基金会Bases担任职务 [1] - 作者运营独立历史播客Storiopolis 内容涵盖金融市场历史 [1] 披露声明 - 作者未持有任何提及公司的股票或衍生品头寸 [2] - 作者未来72小时内无计划建立相关头寸 [2] - 文章内容仅代表作者个人观点 未获得除Seeking Alpha外的任何报酬 [2] 平台声明 - Seeking Alpha声明其分析师包含专业投资者和个人投资者 [3] - 平台强调分析师观点不代表Seeking Alpha整体意见 [3] - 平台明确表示不提供具体投资建议 不持有证券交易牌照 [3]